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Abstract A comparison of the effects of inhibitors of membrane
fusion on the uptake of asialoglycoprotein and transferrin by
primary rat hepatocytes was made. This showed that while high
potassium medium inhibited the degradation but not the uptake
of asialoorosomucoid, both transferrin endocytosis and iron
delivery to the cells were unaffected. This difference between the
two pathways was also observed with an inhibitor of phospho-
lipase A2, bromophenacyl bromide. With the latter, it was found
that the asialoglycoproteins failed to traverse from a low-density
to a high-density intracellular compartment, implying a role for
phospholipase A2 in the trafficking of asialoglycoprotein
receptor but not that for transferrin or iron. This demonstrates
that, after its release from transferrin, iron is transported to the
cytoplasm directly from the early endosome without the need for
fusion of the iron-containing vesicle with a lysosome.
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1. Introduction
The asialoglycoprotein receptor, present on the surface of
primary hepatocytes, functions in the clearance of desialylated
proteins from the plasma. It recognises, and binds, exposed
galactose residues and target proteins are endocytosed and
¢nally degraded in the lysosomes [1]. Early events in the up-
take of asialoglycoproteins have been fairly well characterised
and these are common to another major endocytic pathway,
that of transferrin [2]. Both are dependent on clathrin-assisted
invagination of the plasma membrane, followed by accumu-
lation in an intracellular sorting compartment (CURL). Fol-
lowing this, it is thought that the pathways for the ligands
may diverge, while the receptors are recycled, probably by the
same mechanism. In a previous study, we compared the fate
of transferrin and asialotransferrin when taken up via the
transferrin receptor and the asialoglycoprotein receptor [3].
This showed that transferrin could be either degraded or re-
cycled depending on which receptor it bound to initially. Dur-
ing that study we also observed that iron could be delivered to
the cell from transferrin taken up via the asialoglycoprotein
receptor, which suggests that both iron and asialoglycoprotein
delivery could be dependent on their delivery to other com-
partments downstream of CURL. Two mammalian cell trans-
membrane metal transporters have recently been described.
Nramp1 [4] is restricted to lysosomal membranes while the
closely related Nramp2 is found in endosomes [5]. The ques-
tion arises whether under normal conditions, following release
of iron from transferrin in hepatocytes, the metal is immedi-
ately released from the endosome or follows an endocytic
pathway towards the multi-vesicular vesicles/lysosomes before
being released from the membrane-bound compartment to the
cytoplasm.
A number of studies have made use of metabolic inhibitors
to de¢ne the biochemical events in protein endocytic path-
ways. For instance, incubation of cells in the absence of so-
dium ions inhibited the delivery of the asialoprotein to the
lysosomes while the uptake process was not [6,7]. Similarly,
inhibitors of phospholipase A2 have been shown to interfere
[8]. Because these inhibitors may act at points in the pathways
where transferrin and asialoglycoprotein uptake diverge we
wished to compare their activities on the two pathways to
uncover any di¡erences. We found that neither inhibitor pre-
vented uptake of transferrin or iron while asialoglycoprotein
accumulated in a light vesicle in an undegraded form, suggest-
ing that the pathways diverge prior to the fusion of endo-
somes and that the iron uptake pathway is independent of
this event implying that iron is released from an early endo-
some.
2. Materials and methods
2.1. Proteins
Rat transferrin was puri¢ed from pooled serum using ion exchange
chromatography as described before [9]. Human orosomucoid (Sigma,
Poole, UK) was desialylated as previously described [3] and radio-
labelled with 125I (NaI from Amersham, Bucks, UK) using lactoper-
oxidase-Sepharose [10]. Transferrin was made iron-free by dialysis
against citrate bu¡er, labelled to 98% saturation with 59FeCl3 (Amer-
sham) and then labelled with 125I [11]. Unbound 125I and 59Fe-citrate
were removed by passage of the protein through Dowex 1-X8 anion
exchange resin, equilibrated with 25 mM HEPES, to yield labelled
proteins in which the 125I label was 97% precipitable with 5% tri-
chloroacetic acid (TCA).
2.2. Hepatocytes
Male Wistar rats (250^300 g) were anaesthetised with thiopental
and the livers were perfused with collagenase as described before
[12,13]. Cells were suspended in minimal essential medium (MEM)
(Life Technologies, Fife, UK) with 1% bovine serum albumin (BSA,
fraction V, Sigma). At least 95% of the cells excluded trypan blue.
2.3. Incubation procedures
Hepatocytes (7^12U106 cells/ml in MEM) were incubated at 37‡C
in a volume of 2.5 ml in a shaking water bath under 5% CO2/air.
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Bromophenacyl bromide (BPB), dissolved in dimethyl sulphoxide, was
added to give ¢nal concentrations of 100^1000 WM. A series of experi-
ments showed that a concentration of 500 WM gave maximum e¡ects
without compromising cell viability and so this was used throughout
the experiments described. Control incubations, containing just di-
methyl sulphoxide, were performed in parallel and no e¡ects of the
solvent were observed. In experiments with high-potassium bu¡er [6]
the cells were washed once in this bu¡er and then suspended, at the
same cell density as those in MEM, in K bu¡er containing 1% BSA
and incubated under air. After 20 min, cells were cooled rapidly on ice
and 125I-labelled asialoorosomucoid was added to give a ¢nal concen-
tration of 5 Wg/ml. After 30 min cells were washed three times in ice-
cold MEM, re-suspended in pre-warmed medium containing the in-
hibitor and the incubation continued at 37‡C. For experiments with
transferrin, cells were taken through the same procedure in the ab-
sence of labelled protein and 59Fe-125I-labelled diferric rat transferrin
(20 Wg/ml) was added when the cells were re-suspended in warm me-
dium. Samples (0.3 ml) were taken at intervals into ice-cold phos-
phate-bu¡ered saline (PBS) containing EGTA (5 mM) to release sur-
face-bound asialoorosomucoid into the medium, and the cells were
centrifuged at 400Ugav for 3 min. The supernatants were collected
and those containing asialoorosomucoid were made 10% with TCA
and left overnight on ice. The cells were washed a further three times
and those with asialoorosomucoid were suspended in 10% TCA. The
TCA suspensions were centrifuged at 900Ugav and the pellets and
supernatants collected. These, together with the cell pellets containing
59Fe-125I-labelled transferrin, were then counted in a dual channel
LKB Compugamma gamma-counter.
2.4. Intracellular distribution of ligands
Hepatocytes (5U106/ml) were treated as above but after incubation
at 37‡C samples were taken into ice-cold PBS, washed twice in PBS,
once in 0.25 M sucrose/10 mM EDTA/10 mM Tris^HCl pH 7.4, and
then re-suspended in this sucrose bu¡er. They were then homogenised,
on ice, with 40 strokes of a Dounce homogeniser and applied to a
Percoll (Pharmacia, St Albans, UK) gradient as before [14]. Following
centrifugation, fractions were removed by piercing the bottom of the
tubes for counting of radioactivity and assays of marker enzymes
5P-nucleotidase and acid phosphatase [14].
3. Results
To investigate the uptake of asialoorosomucoid by hepato-
cytes the cells were ¢rst surface-labelled with labelled proteins
in the cold, washed and then warmed rapidly to 37‡C to allow
internalisation of the ligands. As shown in Fig. 1A there was a
steady loss of ligand from the surface of the cells as the in-
cubation proceeded which was balanced by the accumulation
of intracellular protein. After a lag of 30 min, acid-soluble
label began to appear in the medium and this accumulated
more rapidly towards the end of the incubation period. There
was no evidence for the accumulation of acid-soluble product
within the cells.
When the cells were incubated in the high-potassium bu¡er,
although loss of material from the surface was blunted, up-
take continued to occur at a substantial rate and this was
associated with accumulation of the whole protein in the cells
(Fig. 1B). However, under these conditions there was no evi-
dence for any degradation of the protein taken up or any
accumulation of degradation products within the cell. Very
similar results were obtained when the cells were incubated
with the phospholipase A2 inhibitor BPB, and in the experi-
ment shown, at 90 min, degraded protein release was de-
Fig. 1. E¡ect of BPB and high potassium on hepatocyte uptake and
degradation of asialoorosomucoid. Rat hepatocytes, with surface-
bound 125I-asialoorosomucoid, were incubated at 37‡C and sampled
at times into PBS with EGTA (5 mM). Label associated with the
cells, which was TCA-soluble (R) or insoluble (b) and label in the
medium which was TCA-soluble (S) or insoluble (F) was deter-
mined. A: Cells in medium alone. B: Cells in medium with high po-
tassium. C: Cells in medium with BPB. These experiments were re-
peated on at least six occasions with similar results.
Fig. 2. E¡ect of BPB and high potassium on hepatocyte uptake of
transferrin and iron. Rat hepatocytes were incubated with 125I-59Fe-
labelled rat transferrin and sampled over time to monitor iron (a)
and transferrin (b) uptake. A: Cells in medium alone. B: Cells in
medium with high potassium. C: Cells in medium with BPB.
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creased by 85% from 522 ng/106 cells to 78.5 ng/106 cells (Fig.
1C).
In contrast, when the uptake of transferrin and iron was
measured under the same conditions neither high-potassium
bu¡er (Fig. 2B) nor BPB (Fig. 2C) had any measurable e¡ect
on the uptake of the protein or the metal. It was con¢rmed
that uptake was occurring via the transferrin receptor by per-
forming incubations in the presence of excess unlabelled trans-
ferrin and under these conditions, the iron uptake was abol-
ished, as was transferrin uptake (Fig. 2D).
To investigate the intracellular fate of the asialoorosomu-
coid, cells were incubated as above, then homogenised and
intracellular components separated on Percoll gradients dur-
ing the incubation period. As can be seen in Fig. 3 initially
most of the ligand was associated with plasma membrane
components as shown by a high content of 5P-nucleotidase
(Fig. 3, bottom panel) but as the incubation proceeded protein
was lost from this compartment and appeared further down
the gradient in denser areas some of which were high in acid
phosphatase (Fig. 3, bottom panel). Soluble material was also
released from the cells and appeared above the gradient and
by 75 min, in this experiment, most of the material had been
cleared from the cells. In the presence of BPB, however, even
after 75 min incubation the protein was still associated with
intracellular compartments and there was no evidence of deg-
radation products being released (Fig. 4). Furthermore,
although the protein showed a shift to a higher-density com-
partment there was no transfer of protein to high-density
regions of the gradient where lysosomes would be expected,
as shown by the distribution of the acid phosphatase (Fig. 3,
bottom panel).
4. Discussion
The inhibitors we have investigated have very di¡erent
mechanisms of action but they may act at similar points in
the endocytic pathway. Barbieri et al. [15] have shown that in
high-potassium bu¡er the fusion of isolated endosomes was
inhibited probably through its actions on the rab5 protein.
BPB, in contrast, is a potent inhibitor of phospholipase A2
and endosome fusion [8] and results suggest that this enzyme
activity is important in fusion of early endosomes rather than
more mature later endocytic compartments. However, phos-
pholipase A2 found in reticulocyte endocytic vesicles, which
are very active in transferrin endocytosis, is not inhibited by
BPB [16]. There are several forms of cellular phospholipase
A2 and the high-molecular-weight membrane-associated
forms such as that in the reticulocyte vesicle are known not
to be inhibited by BPB [17] and would probably not be in-
volved in vesicle fusion. A more likely target is the low-mo-
Fig. 3. Distribution of asialoorosomucoid in control hepatocyte in-
tracellular compartments separated on Percoll density gradients.
Cells were incubated with 125I-labelled protein, sampled at intervals,
washed, homogenised and fractionated on Percoll density gradients.
Distribution of marker enzymes 5P-nucleotidase (F) and acid phos-
phatase (R) in the gradients was also assessed.
Fig. 4. Distribution of asialoorosomucoid following incubation in
BPB in hepatocyte intracellular compartments separated on Percoll
density gradients. Cells were incubated as in Fig. 3 but in the pres-
ence of BPB.
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lecular-weight cytoplasmic phospholipase A2 which is inhibit-
able by BPB [17]. In isolated vesicle preparations arachidonic
acid can reconstitute fusion of vesicles in the presence of in-
hibited phospholipase A2 [8], suggesting this product of the
enzyme controls the fusion process.
We have shown a very distinct di¡erence in the e¡ects of
high potassium bu¡er and BPB on the transferrin and asialo-
glycoprotein uptake pathways in primary hepatocytes. While
the receptors for these two pathways follow very similar en-
docytic and recycling processes, the ligands, which bind to
them, su¡er di¡erent fates. Asialoglycoproteins are destined
for degradation in lysosomes while transferrin is recycled
along with its receptor for another round of iron delivery
elsewhere. However, it is largely apo-transferrin that is re-
cycled to the surface [18] while its passenger iron atoms are
deposited in the cell for incorporation into enzymes or for
storage in cytoplasmic ferritin. Thus, iron and asialoglycopro-
teins are both retained by hepatocytes, but the contrasting
e¡ects of the inhibitors on these suggest that their handling
by the cell is di¡erent.
Inhibition of phospholipase A2 has been shown to prevent
plasma membrane invagination during phagocytosis [19] but
its lack of inhibition in both asialoorosomucoid and trans-
ferrin uptake suggests that there is no requirement for phos-
pholipase A2 activity in clathrin-dependent endocytosis. Asia-
loorosomucoid, however, accumulated undegraded in a low-
density vesicle after endocytosis. This could have been a mul-
ti-vesicular vesicle, which are of similar density to early endo-
somes [2], but, in view of the results described above on the
importance of phospholipase A2 in the earlier stages of endo-
cytosis [8], is more likely to have been an early endosome
compartment. It is in this compartment that sorting of ligands
and receptors takes place [2], and because of the lack of in-
hibition by BPB and potassium on iron uptake, the results
suggest that iron removal from transferrin also occurs here.
If this is the case then there is no requirement for fusion of
this vesicle with a multi-vesicular vesicle or lysosomes for iron
release to occur. Indeed, in previous work we showed that
iron could be directly released in an ATP-dependent manner
from isolated vesicles in vitro [20]. However, inhibition of
lysosome function has been shown to prevent ferritin iron
recycling [21,22], which suggests that the later vesicles are
capable of releasing iron to the cytoplasmic acceptors. Lyso-
somes in macrophages are known to express the metal trans-
port protein Nramp1, which is capable of transporting iron
[4]. However, it is not clear in which direction this protein
directs the iron, since there are reports of it releasing iron
from lysosomes to the cytoplasm [23^25] and of promoting
uptake of cytoplasmic iron into phagosomes [26]. Early endo-
somes do not express Nramp1 [5] but instead have a related
protein, Nramp2 [27], which co-localises with transferrin in
haemopoietic cell precursors [5]. However, the relative expres-
sion of these protein in the hepatocyte has not been reported,
but since these cells are the site for the body’s major ferritin
iron store, which is rapidly mobilised when needed [28^31], it
would seem that both proteins are likely to be expressed by
these cells. The results presented in this paper suggest that
even if it is expressed, Nramp1 is unlikely to play a role in
transferrin-iron uptake by hepatocytes, since fusion of the
endosome with the late vesicles/lysosomes likely to express
this protein was not involved in uptake of iron. Our previous
work showed that interference with the iron uptake process
can lead to iron transferrin being returned to the surface with-
out iron removal [18] and so iron transfer from this early
endosome compartment is likely to be the rate-limiting step
in iron uptake.
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